Chardan Capital Weighs in on Seres Therapeutics, Inc.’s FY2025 Earnings (NASDAQ:MCRB)

Seres Therapeutics, Inc. (NASDAQ:MCRB) – Equities researchers at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for Seres Therapeutics in a research note issued to investors on Wednesday, August 14th. Chardan Capital analyst K. Nakae forecasts that the biotechnology company will earn ($0.82) per share for the year. Chardan Capital has a “Buy” rating and a $1.25 price target on the stock. The consensus estimate for Seres Therapeutics’ current full-year earnings is ($1.03) per share.

Other equities research analysts have also issued reports about the stock. Canaccord Genuity Group reiterated a “buy” rating and set a $10.00 price target on shares of Seres Therapeutics in a research note on Wednesday. Oppenheimer reiterated a “market perform” rating on shares of Seres Therapeutics in a research report on Friday, June 7th. Finally, StockNews.com cut Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, August 13th.

Seres Therapeutics Trading Down 0.6 %

MCRB stock opened at $0.88 on Friday. The stock has a market cap of $133.24 million, a P/E ratio of -1.47 and a beta of 1.97. Seres Therapeutics has a twelve month low of $0.54 and a twelve month high of $3.67. The company’s 50 day moving average is $0.97 and its two-hundred day moving average is $0.94.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.08. During the same period in the previous year, the company posted $0.36 earnings per share.

Institutional Investors Weigh In On Seres Therapeutics

Several large investors have recently modified their holdings of MCRB. Point72 Asia Singapore Pte. Ltd. acquired a new position in Seres Therapeutics in the 2nd quarter valued at $92,000. Point72 DIFC Ltd acquired a new position in shares of Seres Therapeutics during the second quarter worth about $64,000. Providence Wealth Advisors LLC raised its holdings in Seres Therapeutics by 49.5% during the second quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company’s stock worth $58,000 after purchasing an additional 25,250 shares in the last quarter. Virtu Financial LLC acquired a new stake in Seres Therapeutics in the first quarter valued at about $73,000. Finally, Vanguard Group Inc. boosted its holdings in Seres Therapeutics by 12.1% in the 1st quarter. Vanguard Group Inc. now owns 6,734,821 shares of the biotechnology company’s stock valued at $5,213,000 after purchasing an additional 729,514 shares in the last quarter. Hedge funds and other institutional investors own 59.34% of the company’s stock.

Insider Buying and Selling at Seres Therapeutics

In other news, insider Teresa L. Young sold 24,480 shares of the stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $1.08, for a total transaction of $26,438.40. Following the completion of the sale, the insider now owns 78,178 shares in the company, valued at $84,432.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 5.10% of the stock is currently owned by company insiders.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.